Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Xencor (United States) | Researchclopedia

Back to institutions

Xencor (United States)

Monrovia, Californiacompany

278

Works

64,418

Citations

137

h-index

Top Research Topics

Monoclonal and Polyclonal Antibodies Research CAR-T cell therapy research Glycosylation and Glycoproteins Research

Top Researchers

Jerrold M. Olefsky UC San Diego Health System

672 works91,778 citationsh-index: 147

Recent Research

An <scp>IQ</scp> Consortium Perspective on the <scp>FDA</scp> Guidance for Assessment of Pharmacokinetics in Participants With Impaired Renal Function

Yan Jin,Ashish Sharma,et al.

20260 citations

Chronic Lymphocytic Leukemia Research

T-cell and B-cell Immunology

Immune Cell Function and Interaction

Immunotherapy and Immune Responses

Cancer Immunotherapy and Biomarkers

Biosimilars and Bioanalytical Methods

Immunodeficiency and Autoimmune Disorders

Lymphoma Diagnosis and Treatment

Protein purification and stability

John H. Stone AstraZeneca (United Kingdom)

647 works48,522 citationsh-index: 94

Donald J. Zack Johns Hopkins University

528 works30,550 citationsh-index: 94

Christopher Peterson Carilion Clinic

318 works27,339 citationsh-index: 72

Jiali Gao University of Minnesota

426 works23,345 citationsh-index: 82

David M. Ferguson University of Minnesota

165 works23,188 citationsh-index: 45

P0984 Phase 1 Interim Results for XmAb942, a Potential Best-in-Class, Long-Acting Anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease

M Osterman,S. Aggarwal,et al.

20260 citations

17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433)

Chet Bohac,Sumanta Pal,et al.

20250 citations

A phase I, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (Claudin 6 x CD3) T-cell engaging bispecific antibody in advanced solid tumors

Nicole Nevadunsky,David Levitz,et al.

20250 citations

Opportunities and Challenges of Hepatic Impairment Physiologically Based Pharmacokinetic Modeling in Drug Development—An <scp>IQ</scp> Perspective

Hisham Qosa,Islam R. Younis,et al.

20250 citations

A phase 1, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (claudin-6 x CD3) T-cell engaging bispecific antibody in subjects with germ cell tumors and other advanced solid tumors.

David Levitz,Martin Gutierrez,et al.

20252 citations